Guidance for Integra LifeSciences Holdings Corporation (IART)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
Q1 2024 | $0.53 – $0.57 | $0.75 | $360.00M – 365.00M | $380.90M | = Maintained | Details |
2023 | $3.43 – $3.51 | $3.48 | $1.60B – 1.62B | $1.61B | = Maintained | Details |
2023 | $3.43 – $3.51 | $3.52 | $1.60B – 1.62B | $1.62B | = Maintained | Details |
2023 | $3.10 – $3.14 | $3.14 | $1.54M – 1.55M | $1.56M | = Maintained | Details |
Q2 2023 | $0.75 – $0.79 | $0.85 | $396.00M – 400.00M | $404.80M | = Maintained | Details |
2022 | $3.27 – $3.35 | $3.31 | N/A | N/A | = Maintained | Details |
2022 | $3.21 – $3.29 | $3.31 | $1.56B – 1.58B | $1.59B | = Maintained | Details |
2022 | $3.29 – $3.33 | $3.15 | N/A | N/A | = Maintained | Details |
2022 | $3.27 – $3.35 | $3.42 | $1.58B – 1.60B | $1.63B | = Maintained | Details |
Q4 2022 | $0.87 – $0.91 | $0.88 | $391.00M – 403.00M | $403.50M | = Maintained | Details |
2021 | $2.86 – $2.93 | $2.92 | $1.52B – 1.54B | $1.54B | = Maintained | Details |
2021 | $2.86 – $2.93 | $2.90 | $1.53B – 1.54B | $1.53B | = Maintained | Details |
2021 | $3.16 – $3.20 | $3.04 | $1.54B – 1.55B | $1.54B | = Maintained | Details |
2021 | $2.98 – $3.05 | $2.92 | $1.54B – 1.55B | $1.53B | = Maintained | Details |
2021 | $2.86 – $2.93 | $2.90 | $1.53B – 1.54B | $1.53B | = Maintained | Details |
Q1 2021 | $0.54 – $0.58 | $0.64 | $345.00M – 355.00M | $359.90M | = Maintained | Details |
2020 | $3.00 – $3.05 | $3.00 | $1.55B – 1.57B | $1.59B | = Maintained | Details |
2019 | $2.65 – $2.72 | $2.65 | $1.52M – 1.53M | $1.53M | = Maintained | Details |
2019 | $2.65 – $2.72 | $2.69 | $1.52B – 1.53B | $1.52B | = Maintained | Details |
2019 | $2.70 – $2.75 | $2.73 | $1.52B – 1.52B | $1.52B | = Maintained | Details |
2019 | $2.70 – $2.75 | $2.70 | $1.52B – 1.53B | $1.52B | = Maintained | Details |
2018 | $2.25 – $2.35 | $2.30 | N/A | N/A | = Maintained | Details |
2018 | $2.34 – $2.42 | $2.33 | $1.47B – 1.49B | $1.48B | = Maintained | Details |
2018 | $2.36 – $2.42 | $2.40 | $1.48M – 1.49M | $1.49M | = Maintained | Details |
2018 | $2.36 – $2.42 | $2.40 | $1.47M – 1.47M | $1.49M | = Maintained | Details |
2017 | $1.88 – $1.94 | $1.91 | $1.12B – 1.14B | $1.13B | = Maintained | Details |
2017 | $1.88 – $1.94 | $1.93 | $1.12B – 1.14B | $1.11B | = Maintained | Details |
2017 | $1.83 – $1.87 | $1.91 | N/A | N/A | Lowered | Details |
Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
2016 | $3.35 – $3.50 | $3.43 | $975.00M – 1000.00M | $974.20M | = Maintained | Details |
2016 | $3.38 – $3.50 | $3.43 | $985.00M – 1000.00M | $987.00M | = Maintained | Details |
2016 | $3.43 – $3.53 | $3.44 | N/A | N/A | Raised | Details |
2016 | $3.47 – $3.53 | $3.48 | N/A | N/A | = Maintained | Details |
2015 | $3.05 – $3.23 | $3.27 | $960.00M – 980.00M | $976.80M | = Maintained | Details |
2015 | $3.15 – $3.33 | $3.17 | $965.00M – 980.00M | $972.30M | = Maintained | Details |
2015 | $3.00 – $3.10 | $3.11 | $870.00M – 885.00M | $871.57M | = Maintained | Details |
2015 | $3.05 – $3.10 | $3.06 | $878.00M – 885.00M | $880.30M | Raised | Details |
2014 | N/A | N/A | $920.00M – 940.00M | $932.30M | = Maintained | Details |
2013 | $3.08 – $3.27 | $3.23 | $865.00M – 880.00M | $875.30M | = Maintained | Details |
2013 | $2.50 – $2.60 | $2.53 | $838.00M – 843.00M | $841.46M | = Maintained | Details |
2013 | $2.40 – $2.70 | $2.72 | $840.00M – 852.00M | $855.65M | Lowered | Details |
2012 | $2.93 – $3.06 | $3.04 | $820.00M – 835.00M | $832.10M | = Maintained | Details |
2012 | $2.97 – $3.06 | $3.00 | $820.00M – 835.00M | $826.16M | = Maintained | Details |
2012 | $3.04 – $3.09 | $3.04 | N/A | N/A | Raised | Details |
2012 | N/A | N/A | $828.00M – 838.00M | $829.62M | Raised | Details |
2011 | $2.87 – $3.02 | $2.99 | N/A | N/A | = Maintained | Details |
2011 | $2.88 – $2.96 | $2.93 | N/A | N/A | Lowered | Details |
2011 | $2.92 – $3.02 | $2.98 | $785.00M – 800.00M | $783.55M | = Maintained | Details |